Amgen To Present At The Deutsche Bank 39th Annual Healthcare Conference

THOUSAND OAKS, Calif., May 2, 2014 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will present at the Deutsche Bank 39th Annual Healthcare Conference at 2:50 p.m. ET on Wednesday, May 7, 2014, at the InterContinental Hotel in Boston. Michael Severino, M.D., senior vice president of Global Development and corporate chief medical officer at Amgen, will present at the conference. Live audio of the presentation can be accessed from the Events Calendar on Amgen's website, www.amgen.com, under Investors. A replay of the webcast will also be available on Amgen's website for 90 days following the event.

About Amgen
Amgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing and delivering innovative human therapeutics. This approach begins by using tools like advanced human genetics to unravel the complexities of disease and understand the fundamentals of human biology.

Amgen focuses on areas of high unmet medical need and leverages its biologics manufacturing expertise to strive for solutions that improve health outcomes and dramatically improve people's lives. A biotechnology pioneer since 1980, Amgen has grown to be the world's largest independent biotechnology company, has reached millions of patients around the world and is developing a pipeline of medicines with breakaway potential.

For more information, visit www.amgen.com and follow us on www.twitter.com/amgen.

CONTACT: Amgen, Thousand Oaks
Kristen Davis, 805-447-3008 (media)
Eric Hyllengren, 805-447-1060 (investors)

Amgen Logo

Logo - http://photos.prnewswire.com/prnh/20081015/AMGENLOGO

SOURCE Amgen

Suggested Articles

Just one week after inking a COVID-19 vaccine deal with the U.S. for 100 million doses, J&J reached a supply agreement twice that size with the EU.

Ahead of a critical flu season, AstraZeneca is upping its manufacturing efforts to deliver more FluMist doses than previously anticipated.

FDA handed NS Pharma’s Viltepso a speedy FDA nod based on the same dystrophin production data that supported two Sarepta drugs' approvals.